Halozyme Therapeutics (HALO) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 68.5% versus a gain of 1.6%. Over five years, HALO leads with a +190.9% price change compared with +35.1% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.36 billion vs $12.47 billion), about 1.2 times the size, while Halozyme Therapeutics is growing revenue faster (+37.6% vs +21.4%).
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.3x vs 11.9x for Neurocrine Biosciences). Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | NBIX |
|---|---|---|
| Share price | $109.84 | $141.25 |
| Market cap | $12.47B | $14.36B |
| 1-day change | -0.86% | -1.55% |
| YTD return | +63.21% | -0.41% |
| 1-year return | +68.47% | +1.56% |
| 5-year return | +190.89% | +35.12% |
| P/E ratio (TTM) | 32.12 | 20.71 |
| Forward P/E | 10.33 | 11.89 |
| EPS (TTM) | $3.42 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | $2.86B |
| Revenue growth (YoY) | +37.55% | +21.45% |
| Net income (latest FY) | $316.89M | $478.60M |
| Gross margin | 83.62% | 98.18% |
| Operating margin | 33.58% | 21.64% |
| Net margin | 22.69% | 16.73% |
| 52-week high | $116.85 | $186.12 |
| 52-week low | $61.23 | $122.14 |
| Distance from 52-week high | -6.00% | -24.11% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.36% | +46.75% |
| Average volume | 2.18M | 1.30M |
| Shares outstanding | 113.50M | 101.65M |
| Employees | 423 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HALO has outperformed NBIX by 66.9 percentage points over the past year.
- Halozyme Therapeutics trades at a higher earnings multiple (32.1x vs 20.7x trailing P/E).
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs +21.45%).
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
HALO vs NBIX FAQ
Which is bigger, Halozyme Therapeutics or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.36B compared with $12.47B for Halozyme Therapeutics (HALO).
Which stock has performed better over the past year, HALO or NBIX?
HALO returned +68.47% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HALO or NBIX?
NBIX has the lower trailing P/E at 20.7, versus 32.1 for HALO. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Halozyme Therapeutics and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.